BioMarin Pharmaceutical Inc.
About BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. In 1997, the company was founded to make a big difference in small patient populations, focusing on giving much-needed attention to the underserved communities of those with rare diseases. BioMarin sought to help patients whose voices could not always be heard and treat conditions that were not always in mainstream medical conversations. Throughout its history, BioMarin has worked tirelessly to make a difference by pursuing bold science. The company’s first approved therapy was inspired by a father who refused to accept there was no therapy for his son’s rare diagnosis. That relentless pursuit to change the course of his son’s future through the power of science is at the core of who BioMarin is today.
Through the company’s expertise in genetics and molecular biology, BioMarin has developed eight first or best-in-class targeted therapies that address the root cause of the conditions it seeks to treat, helping to better the lives of those struggling with rare genetic disease. The company’s purposeful and scientifically precise team of physicians and scientists has honed each treatment modality to seek transformative therapies.
Now, BioMarin seeks to make an even greater impact by applying the same science-driven, patient-forward approach that propelled the last 25 plus years of drug development to larger genetic disorders, as well as genetic subsets of more common conditions. Each drug candidate pursued is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address. The company believes that applying its knowledge to make a transformative impact is not just a calling, but an obligation to those who will benefit most. The more innovative solutions developed, the more lives BioMarin can impact.
841 articles about BioMarin Pharmaceutical Inc.
-
BioMarin Pharmaceutical Inc. Results From Phase 1 Clinical Study of PEG-PAL in PKU and Update on Phase 2 Clinical Study
6/9/2009
-
Doe & Ingalls of California, LLC Selected as Distribution Partner to BioMarin Pharmaceutical Inc.
6/8/2009
-
BioMarin Pharmaceutical Inc. to Present at the William Blair Growth Stock Conference
6/3/2009
-
BioMarin Pharmaceutical Inc. Receives 2009 Corporate Award for the Development of Kuvan
5/15/2009
-
BioMarin Pharmaceutical Inc. to Present at the Deutsche Bank Health Care Conference
5/12/2009
-
BioMarin Pharmaceutical Inc. Announces First Quarter 2009 Financial Results
5/1/2009
-
BioMarin Pharmaceutical Inc. Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
4/22/2009
-
BioMarin Pharmaceutical Inc. to Host First Quarter 2009 Financial Results Conference Call and Webcast on Thursday, April 30 at 5:00 p.m. ET (23:00 CET)
4/9/2009
-
BioMarin Pharmaceutical Inc. Returns Rights to Lupus Drug to La Jolla Pharmaceutical Company
4/2/2009
-
BioMarin Pharmaceutical Inc. Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
3/30/2009
-
BioMarin Pharmaceutical Inc. to Present at the 4th Annual Citi Biotech Day
3/25/2009
-
BioMarin Pharmaceutical Inc.'s Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA
3/18/2009
-
BioMarin Pharmaceutical Inc. to Present at the Cowen and Company 29th Annual Health Care Conference
3/10/2009
-
BioMarin Pharmaceutical Inc. to Present at the Barclays Capital Global Healthcare Conference
3/4/2009
-
BioMarin Pharmaceutical Inc. Appoints Dr. Henry J. Fuchs as Senior Vice President and Chief Medical Officer
3/2/2009
-
BioMarin Pharmaceutical Inc. Announces Fourth Quarter and Full Year 2008 Financial Results 2008 First Profitable Full Year Conference Call and Webcast to Be Held Today at 5:00 p.m. ET
2/19/2009
-
La Jolla Pharmaceutical Company and BioMarin Pharmaceutical Inc. (JOBS) Stop Developing Lupus Drug
2/12/2009
-
BioMarin Pharmaceutical Inc. Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant
2/3/2009
-
BioMarin Pharmaceutical Inc. Release: Naglazyme Approved by Brazil's National Health Surveillance Agency
2/3/2009
-
BioMarin Pharmaceutical Inc. to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
1/28/2009